Neurodegenerative Disease Market Size (2024 - 2029)

The market size of the Neurodegenerative Disease sector is predicted to expand significantly in the coming years, despite experiencing a temporary slowdown due to the COVID-19 pandemic's impact on clinical trials, research, and development activities. The market's growth is expected to be driven by factors such as the rising prevalence of neurological disorders, increasing global awareness, and a robust product pipeline for disease treatment. However, challenges such as stringent regulatory guidelines and the patent expiry of treatment products may pose potential hindrances to market expansion.

Market Size of Neurodegenerative Disease Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Neurodegenerative Disease Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 55.12 Billion
Market Size (2029) USD 77.82 Billion
CAGR (2024 - 2029) 7.14 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Neurodegenerative Disease Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Neurodegenerative Disease Market Analysis

The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).

The key growth determinants of the market include the increasing number of neurological disorders, growing awareness globally, and a strong lineup of products for treating neurodegenerative diseases. As the global population grows and people live longer on average, more people are experiencing neurological disorders.

According to data from the National Institute of Environmental Health Sciences, as of June 2022, around 6.2 million Americans had Alzheimer's disease. Furthermore, a study published in the Lancet Journal in March 2024 showed that neurological disorders contribute to 3.4 billion disability-adjusted life-years (DALYs) worldwide. This high burden of neurological disorders is anticipated to increase the demand for treatments and effective methods, driving growth in the neurodegenerative disease market.

The market is set to expand due to increasing attention to developing products for neurodegenerative diseases. For instance, in December 2023, Alpha Cognition reported that the US FDA accepted its New Drug Application for ALPHA-1062, intended for treating Mild-to-Moderate Alzheimer's Disease. ALPHA-1062 is a drug that inhibits acetylcholinesterase, with fewer expected side effects on the stomach.

In March 2024, Prilenia Therapeutics BV shared its plan to submit a Marketing Authorization Application (MAA) for pridopidine to the Medicinal Products for Human Use (CHMP) committee under the European Medicines Agency, seeking approval to treat Huntington's disease (HD). This trend of developing products and obtaining regulatory approvals shows a growing effort to address neurodegenerative diseases, driving market growth.

These factors are expected to contribute to the market's growth during the forecast period. However, strict regulatory requirements and the expiration of patents for treatments of neurodegenerative diseases are significant factors that could hinder market growth.

Neurodegenerative Disease Industry Segmentation

As per the scope of the report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and neuron degradation leads to neurons' gradual death.

 The market is segmented by indication type, drug type, and geography. By indication type, the market is segmented into Parkinson's disease, Alzheimer's Disease, multiple sclerosis, Huntington's disease, and other indication types. By drug type, the market is segmented into N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors, dopamine agonists, immunomodulatory drugs, and other drug types. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the market sizes and forecasts in 17 countries across the major regions. For each segment, the market size is provided in terms of value (USD).

By Indication Type
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Other Indication Types
By Drug Type
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Other Drug Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Neurodegenerative Disease Market Size Summary

The Neurodegenerative Disease Market is expected to experience significant growth in the upcoming years. This growth is anticipated due to an increase in the prevalence of neurological disorders, growing awareness among the population, and a robust pipeline of products for the treatment of neurodegenerative diseases. However, the COVID-19 pandemic has impacted the market growth due to disruptions in clinical trials, research, and development activities. Despite this, the market has seen a positive impact in the later phase as research and development activities resumed. The market is witnessing trends such as an expected significant growth in the Alzheimer's Disease segment and North America dominating the market over the forecast period. The Alzheimer's segment is expected to grow due to the increasing prevalence of the disease and the launch of new products and research and development activities. North America's dominance in the market is attributed to the increasing number of neurological disorders and research and development activities focused on developing treatments for such diseases. Despite the promising growth, the market faces challenges such as stringent regulatory guidelines and the patent expiry of neurodegenerative disease treatment products.

Explore More

Neurodegenerative Disease Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Neurological Disorders

      2. 1.2.2 Increasing Public Awareness

      3. 1.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment

    3. 1.3 Market Restraints

      1. 1.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products

      2. 1.3.2 Stringent Regulatory Guidelines

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Indication Type

      1. 2.1.1 Parkinson's Disease

      2. 2.1.2 Alzheimer's Disease

      3. 2.1.3 Multiple Sclerosis

      4. 2.1.4 Huntington Disease

      5. 2.1.5 Other Indication Types

    2. 2.2 By Drug Type

      1. 2.2.1 N-methyl-D-aspartate Receptor Antagonists

      2. 2.2.2 Cholinesterase Inhibitors

      3. 2.2.3 Dopamine Agonists

      4. 2.2.4 Immunomodulatory Drugs

      5. 2.2.5 Other Drug Types

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Neurodegenerative Disease Market Size FAQs

The Neurodegenerative Disease Market size is expected to reach USD 55.12 billion in 2024 and grow at a CAGR of 7.14% to reach USD 77.82 billion by 2029.

In 2024, the Neurodegenerative Disease Market size is expected to reach USD 55.12 billion.

Neurodegenerative Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)